[{"orgOrder":0,"company":"Kirin Holdings","sponsor":"Biofortis Clinical Research, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Citicoline Sodium","moa":"LicC protein","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kirin Holdings","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kirin Holdings \/ Biofortis Clinical Research, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Kirin Holdings \/ Biofortis Clinical Research, Inc."},{"orgOrder":0,"company":"Kirin Holdings","sponsor":"The Center for Applied Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Citicoline Sodium","moa":"LicC protein","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Kirin Holdings","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kirin Holdings \/ The Center for Applied Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kirin Holdings \/ The Center for Applied Health Sciences"},{"orgOrder":0,"company":"Omikron Italia","sponsor":"OPIS Spain","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Citicoline Sodium","moa":"LicC protein","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Omikron Italia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Omikron Italia \/ OPIS Spain","highestDevelopmentStatusID":"10","companyTruncated":"Omikron Italia \/ OPIS Spain"}]

Find Clinical Drug Pipeline Developments & Deals for Citicoline Sodium

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Citicoline is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of unspecified medical condition.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          July 28, 2025

                          Lead Product(s) : Citicoline Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : The Center for Applied Health Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Citicoline is a Dietary Supplement drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glaucoma, Open-Angle.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          February 02, 2023

                          Lead Product(s) : Citicoline Sodium

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : OPIS Spain

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Citicoline is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          July 19, 2021

                          Lead Product(s) : Citicoline Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Biofortis Clinical Research, Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank